Oruka Therapeutics’ (ORKA) “Outperform” Rating Reiterated at Wedbush

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “outperform” rating reissued by equities research analysts at Wedbush in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $165.00 price target on the stock. Wedbush’s price objective would suggest a potential upside of 59.34% from the company’s previous close.

A number of other equities research analysts have also issued reports on the stock. Weiss Ratings raised shares of Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 15th. HC Wainwright reiterated a “buy” rating and set a $120.00 price objective on shares of Oruka Therapeutics in a report on Monday, August 3rd. UBS Group increased their price objective on Oruka Therapeutics from $100.00 to $130.00 and gave the stock a “buy” rating in a report on Wednesday, July 1st. Barclays boosted their target price on Oruka Therapeutics from $78.00 to $160.00 and gave the company an “overweight” rating in a research note on Monday, April 27th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $180.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, June 2nd. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $134.30.

Oruka Therapeutics Stock Performance

Shares of NASDAQ ORKA traded down $1.59 during mid-day trading on Tuesday, reaching $103.55. The company had a trading volume of 35,156 shares, compared to its average volume of 1,138,015. The company has a market capitalization of $6.25 billion, a price-to-earnings ratio of -53.67 and a beta of -0.34. The stock has a fifty day moving average of $83.59 and a two-hundred day moving average of $60.75. Oruka Therapeutics has a 12-month low of $13.06 and a 12-month high of $107.55.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). Sell-side analysts forecast that Oruka Therapeutics will post -2.06 earnings per share for the current fiscal year.

Insider Buying and Selling at Oruka Therapeutics

In other news, SVP Arjun Agarwal sold 10,290 shares of the stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $59.07, for a total transaction of $607,830.30. Following the transaction, the senior vice president owned 16,406 shares of the company’s stock, valued at approximately $969,102.42. This represents a 38.55% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Lawrence Otto Klein sold 1,729 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $69.69, for a total value of $120,494.01. Following the completion of the sale, the chief executive officer owned 925,580 shares of the company’s stock, valued at approximately $64,503,670.20. This trade represents a 0.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 188,406 shares of company stock valued at $12,019,683. Corporate insiders own 23.49% of the company’s stock.

Institutional Trading of Oruka Therapeutics

Several large investors have recently modified their holdings of the company. Moody Aldrich Partners LLC bought a new position in Oruka Therapeutics in the 4th quarter worth $3,844,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of Oruka Therapeutics in the first quarter valued at about $1,811,000. SG Americas Securities LLC acquired a new stake in shares of Oruka Therapeutics in the fourth quarter valued at about $251,000. Perceptive Advisors LLC increased its stake in shares of Oruka Therapeutics by 16.4% in the fourth quarter. Perceptive Advisors LLC now owns 1,476,501 shares of the company’s stock worth $44,753,000 after purchasing an additional 208,480 shares during the period. Finally, The Manufacturers Life Insurance Company lifted its position in shares of Oruka Therapeutics by 18.3% during the 1st quarter. The Manufacturers Life Insurance Company now owns 72,563 shares of the company’s stock worth $3,559,000 after purchasing an additional 11,205 shares during the last quarter. 56.44% of the stock is owned by institutional investors.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical?stage biopharmaceutical company focused on the development of novel peptide?based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell?permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.